Details of Disease

General Information of Disease (ID: DISXSU1Y)

• Disease Name: Peripheral vascular disease
• Synonyms: vascular disease, peripheral; disease, peripheral vascular; peripheral vascular disorder; arterial occlusive disease
• Disease Class: BD4Z: Chronic arterial occlusive disease
• Definition: Any disorder affecting blood flow through the veins or arteries outside of the heart.
• Disease Hierarchy:
  DISVS67S: Vascular disease
  DISXSU1Y: Peripheral vascular disease
• ICD Code:
  ICD-11: ICD-11: BD4Z
  ICD-10: ICD-10: I73.9
  ICD-9: ICD-9: 443.9
  Expand ICD-11: 'BD4Z
  Expand ICD-10: 'I73.9
  Expand ICD-9: 443.9
• Disease Identifiers:
  MONDO ID: MONDO_0005294
  MESH ID: D016491
  UMLS CUI: C0085096
  MedGen ID: 38790
  SNOMED CT ID: 400047006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Brilinta	DMBR01X	Approved	Small molecular drug	[1]
Buflomedil	DMG1OPF	Approved	Small molecular drug	[2]
Papaverine	DMCA9QP	Approved	Small molecular drug	[3]
Pentoxifylline	DMU3DNC	Approved	Small molecular drug	[4]
Phentolamine	DMXYJOB	Approved	Small molecular drug	[5]
Treprostinil	DMTIQF3	Approved	Small molecular drug	[6]

This Disease is Treated as An Indication in 14 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alfimeprase	DMVHRL8	Phase 3	NA	[7]
MABp1	DM8D13S	Phase 3	NA	[8]
PLX-PAD cell therapy	DMW0IRA	Phase 3	NA	[9]
Ad2/HIF-1alpha/VP16	DMPMKH4	Phase 2	NA	[10]
Autologous T-lymphocyte cell therapy	DML9Z8D	Phase 2	NA	[11]
Placental expanded stem cell therapy	DMNCUSV	Phase 2	NA	[12]
REG-101	DMG9375	Phase 2	NA	[13]
SH-529	DMGIRM1	Phase 2	NA	[14]
SRM003	DMJ2CCI	Phase 2	NA	[15]
VLTS-589	DM4O17U	Phase 2	NA	[16]
VLTS-934	DMSS0XT	Phase 2	NA	[17]
Vascugel	DM1DVLU	Phase 1/2	NA	[18]
BIBV 308	DMUBMN5	Phase 1	Small molecular drug	[19]
EW-A-401	DM3VC6T	Phase 1	NA	[20]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-74187	DMLIT2D	Discontinued in Phase 3	NA	[21]
Avasimibe	DMFG4OM	Discontinued in Phase 3	Small molecular drug	[22]
XEMILOFIBAN	DMBRYT8	Discontinued in Phase 3	Small molecular drug	[23]
DG041	DMVO9WM	Discontinued in Phase 2	Small molecular drug	[24]
OPC-28326	DMYM8OG	Discontinued in Phase 2	Small molecular drug	[25]
SUN-C5174	DMZ8VI0	Discontinued in Phase 2	NA	[26]
Torcetrapib	DMDHYM7	Discontinued in Phase 2	Small molecular drug	[27]
EG-016	DM7JMVR	Discontinued in Phase 1/2	NA	[28]
Torbafylline	DMRBGI6	Terminated	Small molecular drug	[29]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CTCE-0324	DMEGZHF	Investigative	NA	[30]
MGN-6114	DM5MHTN	Investigative	NA	[31]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
FGF4	TTCEKVZ	moderate	Biomarker	[32]
AHSG	TTKF4WV	Strong	Altered Expression	[33]
F5	TT1O264	Strong	Biomarker	[34]
F7	TTF0EGX	Strong	Genetic Variation	[35]
FABP4	TTHWMFZ	Strong	Biomarker	[36]
P2RY12	TTZ1DT0	Strong	Genetic Variation	[37]
PADI4	TTQHAXM	Strong	Biomarker	[38]
PCSK9	TTNIZ2B	Strong	Altered Expression	[39]
SERPIND1	TT8XSKJ	Strong	Altered Expression	[40]
SRD5A1	TTTU72V	Strong	Genetic Variation	[41]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC6	DT582KR	moderate	Genetic Variation	[42]
SLC2A10	DT3BI6S	Strong	Genetic Variation	[43]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP1A1	DE6OQ3W	Limited	Biomarker	[44]
P3H1	DEW527E	Strong	Biomarker	[45]

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ANGPTL6	OTOQ5W67	Limited	Biomarker	[46]
DAB2IP	OTF456VC	Limited	Biomarker	[47]
ADAMTS7	OTVKZ1DV	moderate	Genetic Variation	[48]
BFAR	OTTBG0V7	moderate	Biomarker	[49]
SERPINA5	OTTZXPGD	moderate	Biomarker	[50]
THBS4	OTA1T9KK	moderate	Biomarker	[51]
DHX40	OTOL02QN	Strong	Biomarker	[38]
FGB	OT6RKLI9	Strong	Genetic Variation	[52]
GCA	OTAJ7ZHG	Strong	Biomarker	[53]
INSIG2	OTX4VY51	Strong	Genetic Variation	[54]
LAD1	OT6YGTVX	Strong	Genetic Variation	[55]
MT1B	OTUA4FFH	Strong	Genetic Variation	[56]
OSBPL10	OT0TFMBE	Strong	Genetic Variation	[57]
PADI1	OT13WAQX	Strong	Biomarker	[58]
PSMD14	OTJWHMZ5	Strong	Biomarker	[58]
SPRTN	OT01D5CE	Strong	Biomarker	[59]
TRIM63	OTUSWA74	Strong	Biomarker	[60]

References

• [1] Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs. 2022 Aug;82(12):1287-1302.
• [2] Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. Circulation. 2008 Feb 12;117(6):816-22.
• [3] Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic. Diabet Med. 1995 Jan;12(1):77-82.
• [4] Pentoxifylline FDA Label
• [5] Phentolamine FDA Label
• [6] Treprostinil FDA Label
• [7] ClinicalTrials.gov (NCT00338585) Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ClinicalTrials.gov (NCT01679990) Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC). U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT00117650) Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1alpha/VP16 Gene Transfer in Patients With Intermittent Claudication. U.S. National Institutes of Health.
• [11] Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012 Mar-Apr;18(2):160-75.
• [12] Clinical pipeline report, company report or official report of Pluristem Therapeutics.
• [13] Clinical pipeline report, company report or official report of Regio Biosciences
• [14] Particulate beta-glucan induces TNF-alpha production in wound macrophages via a redox-sensitive NF- beta-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9.
• [15] ClinicalTrials.gov (NCT01806545) An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT00068133) Trial of VLTS-589 in Subjects With Intermittent Claudication. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT00113009) Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease. U.S. National Institutes of Health.
• [18] ClinicalTrials.gov (NCT00479180) Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT02223013) Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT00080392) EW-A-401 to Treat Intermittent Claudication. U.S. National Institutes of Health.
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008778)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004434)
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5822).
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011559)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012828)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015157)
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031989)
• [29] Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63.
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71).
• [31] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [32] Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review).Int J Mol Med. 2013 Oct;32(4):763-7. doi: 10.3892/ijmm.2013.1444. Epub 2013 Jul 16.
• [33] Association of plasma fetuin-a levels with peripheral arterial disease and lower extremity arterial calcification in subjects with type 2 diabetes mellitus.J Diabetes Complications. 2017 Mar;31(3):599-604. doi: 10.1016/j.jdiacomp.2016.11.006. Epub 2016 Nov 12.
• [34] Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors.J Vasc Surg. 2005 Nov;42(5):1014-8. doi: 10.1016/j.jvs.2005.06.019.
• [35] A two adenine insertion polymorphism in the 3' untranslated region of factor VII gene is associated with peripheral arterial disease but not with venous thrombosis. Results of case-control studies.Thromb Haemost. 2007 Oct;98(4):733-7.
• [36] Positive Association of Serum Adipocyte Fatty Acid Binding Protein Level With Peripheral Artery Disease in Hemodialysis Patients.Ther Apher Dial. 2020 Jun;24(3):300-306. doi: 10.1111/1744-9987.13431. Epub 2019 Oct 9.
• [37] Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease.BMC Med Genet. 2007 Sep 5;8:59. doi: 10.1186/1471-2350-8-59.
• [38] Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites.J Vasc Surg. 2018 Aug;68(2):560-566. doi: 10.1016/j.jvs.2017.11.088. Epub 2018 Mar 1.
• [39] Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association.J Clin Lipidol. 2019 Jul-Aug;13(4):525-537. doi: 10.1016/j.jacl.2019.05.005. Epub 2019 May 16.
• [40] Heparin cofactor II as a novel vascular protective factor against atherosclerosis.J Atheroscler Thromb. 2009 Oct;16(5):523-31. doi: 10.5551/jat.1552. Epub 2009 Sep 3.
• [41] Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease.J Endocrinol Invest. 2008 Dec;31(12):1092-7. doi: 10.1007/BF03345658.
• [42] The prevalence of pseudoxanthoma elasticum: Revised estimations based on genotyping in a high vascular risk cohort.Eur J Med Genet. 2019 Feb;62(2):90-92. doi: 10.1016/j.ejmg.2018.05.020. Epub 2018 May 22.
• [43] SLC2A10 genetic polymorphism predicts development of peripheral arterial disease in patients with type 2 diabetes. SLC2A10 and PAD in type 2 diabetes.BMC Med Genet. 2010 Aug 25;11:126. doi: 10.1186/1471-2350-11-126.
• [44] Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.Toxicol Lett. 2009 Apr 10;186(1):66-72. doi: 10.1016/j.toxlet.2008.10.018. Epub 2008 Oct 28.
• [45] Bilateral giant retinal tears in Osteogenesis Imperfecta.BMC Med Genet. 2018 Jan 12;19(1):8. doi: 10.1186/s12881-018-0521-0.
• [46] Angiopoietin-related growth factor is independently associated with lower extremity peripheral arterial disease.J Diabetes Complications. 2017 Feb;31(2):433-438. doi: 10.1016/j.jdiacomp.2016.10.019. Epub 2016 Oct 27.
• [47] Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm.Nat Genet. 2010 Aug;42(8):692-7. doi: 10.1038/ng.622. Epub 2010 Jul 11.
• [48] Genetic variants rs1994016 and rs3825807 in ADAMTS7 affect its mRNA expression in atherosclerotic occlusive peripheral arterial disease.J Clin Lab Anal. 2018 Jan;32(1):e22174. doi: 10.1002/jcla.22174. Epub 2017 Feb 15.
• [49] A prospective, multi-center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry.Catheter Cardiovasc Interv. 2018 May 1;91(6):1144-1148. doi: 10.1002/ccd.27565. Epub 2018 Mar 7.
• [50] Long-Term Outcomes Following Heart Team Revascularization Recommendations in Complex Coronary Artery Disease.J Am Heart Assoc. 2019 Apr 16;8(8):e011279. doi: 10.1161/JAHA.118.011279.
• [51] Thrombospondin-4 increases with the severity of peripheral arterial disease and is associated with diabetes.Heart Vessels. 2020 Jan;35(1):52-58. doi: 10.1007/s00380-019-01453-7. Epub 2019 Jun 21.
• [52] Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde.Circulation. 1996 Feb 1;93(3):440-9. doi: 10.1161/01.cir.93.3.440.
• [53] Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.Rheumatology (Oxford). 2017 May 1;56(5):753-762. doi: 10.1093/rheumatology/kew482.
• [54] Association of an INSIG2 obesity allele with cardiovascular phenotypes is gender and age dependent.BMC Cardiovasc Disord. 2010 Sep 29;10:46. doi: 10.1186/1471-2261-10-46.
• [55] Incidence and predictors of outcomes after a first definite coronary stent thrombosis.EuroIntervention. 2020 Jul 17;16(4):e344-e350. doi: 10.4244/EIJ-D-19-00219.
• [56] The MTP -493TT genotype is associated with peripheral arterial disease: results from the Linz Peripheral Arterial Disease (LIPAD) Study.Clin Biochem. 2008 Jun;41(9):712-6. doi: 10.1016/j.clinbiochem.2008.02.007. Epub 2008 Feb 21.
• [57] Identification of evidence suggestive of an association with peripheral arterial disease at the OSBPL10 locus by genome-wide investigation in the Japanese population.J Atheroscler Thromb. 2010 Oct 27;17(10):1054-62. doi: 10.5551/jat.4291. Epub 2010 Jul 2.
• [58] Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease.J Surg Res. 2017 Apr;210:124-131. doi: 10.1016/j.jss.2016.11.011. Epub 2016 Nov 11.
• [59] DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
• [60] TLR-4 and VEGF polymorphisms in chronic periaortitis.PLoS One. 2013 May 14;8(5):e62330. doi: 10.1371/journal.pone.0062330. Print 2013.